Open Life Sci. 2016; 11: 110-115 invasion and metastases. These characteristics are results of genetic deregulation. Accumulation of genetic mutations results in increasingly aggressive phenotypes [5] .
Breast Cancer
Breast cancer is the most common malignancy in women in the world and is the leading cause of cancer-related death [1] . Several factors contribute to initiation and progression of breast cancer [2] [3] [4] . Sustaining proliferative signaling, escaping growth inhibition and resisting cell death are hallmarks of cancers. The distinctive capacities of cancer also include inducing angiogenesis, activating mainly applies to p65: p50 dimers, which is released after IκB phosphorylation by the IKK complex and subsequent degradation of this inhibitor. Finally, the heterodimer is translocated to the nucleus and activates the transcription of various target genes including Bcl-2, IL-6, and TNF [22] . To summarize the above, dysregulation of E-cadherin leads to dysfunctions of E-cadherin-mediated signaling pathways, which alters cell polarity, increases cell survival, and promotes EMT process as well as cell invasion and migration [23] . These effects induce cancer initiation and progression, including breast cancer.
Genetic Mutations and Variants of E-Cadherin in Breast Cancer
Genetic mutation is one major mechanism for silencing tumor suppressor genes. E-cadherin acts as a tumor suppressor and downregulation of E-cadherin is observed in various cancers. Frequent E-cadherin gene (CDH1) inactivating mutations have been identified in lobular breast cancers. The lifetime risk of breast cancer in CDH1 gene mutation carriers is on the order of 40% to 50% [24] . E-cadherin has been postulated to function as a potent breast tumor suppressor [25] . E-cadherin downregulation or loss is associated with poor prognosis in breast cancer to nonfunctional APC (adenomatous polyposis coli) or GSK-3β (glycogen synthase kinase3β) [14] . Subsequently, a high level of β-catenins in the cytoplasm translocates into the nucleus, binds to members of the TCF/LEF1 (Transcription Factor/Lymphoid enhancer-binding factor 1) family, and activates the expression of Wnt target genes, including CD44, c-MYC, and MMP7 [15] . Activation of these genes contributes to increased cell proliferation and tumor progression. Hence, it is supposed that by sequestering β-catenin at sites of cell to cell contact, E-cadherin expression can suppress Wnt/β-catenin signaling.
Another pathway frequently overexpressed in breast cancer involves Rho GTPases, with Rho A, Rac1, and Cdc42 extensively studied [16, 17] . In addition, activation of RhoA through an E-cadherin dependent pathway involves the role of EGFR (epidermal growth factor receptor) [18] . Mutations at the E-cadherin extracellular domain may impair the interaction of E-cadherin and EGFR, lead to EGFR activation, and further enhance cell motility through activating RhoA [19] . Moreover, loss of E-cadherin and release of p120-catenin activate the Rac1-MAPK (mitogen activated protein kinase) signaling pathway and promote transformed cell growth [20] . Interestingly, the E-cadherin/catenin complex appears to possess the ability to down modulate NF-κB activity [21] . In mammals, the canonical NF-κB activation pathway Figure 1 . E-cadherin regulated signaling pathways involved in breast cancer, including Rho GTPases, Wnt/β-catenin pathway, NF-κB pathway, EGFR, and Rac-MAPK signaling. Activation of these pathways leads to an increase in cell proliferation, decrease in cell apoptosis, cell migration, and inflammation associated gastric cancer development. Abbreviations: Rho GTPases, Ras homolog guanosine 5'-triphosphates; NF-κB, nuclear factor kappa B; EGFR, epidermal growth factor receptor; MAPK, Mitogen-activated protein kinases.
degradation, which inactivate its functions. Inactivation of E-cadherin decreases cell to cell adhesion and induces aberrant alternations of E-cadherin-associated signaling pathways involved in cell proliferation, EMT process, inflammation, and so forth. These aberrant changes trigger breast cancer development.
The Role of E-cadherin Polymorphisms in Breast Cancer Risk
Genetic polymorphisms are the change of the common DNA sequence in the general population. In contrast with mutations, this type of change does not cause obvious disease. This slight difference occurs in the promoter region, exon or coding sequence, and may affect gene expressions or protein function, leading to different characteristics among individuals. Single-nucleotide polymorphisms (SNPs) are the most common type of variation in the human genome. SNPs provide powerful tools for a variety of medical genetic studies. SNPs occur about once every 1000 base pairs. In recent years there has been an enormous effort by numerous laboratories worldwide to identify the role of genetic mutations in genetic predisposition and disease progression in particular cancers.
A study by Li et al. [32] suggested that interindividual variation in E-cadherin expression may be a result of SNPs in the E-cadherin (CDH1) gene promoter region and in turn lead to individual susceptibility to carcinoma. The literature with regard to CDH1 polymorphisms and breast cancer is limited but increasing. Several studies [39] [40] [41] found a relationship between the -160 C/A polymorphism and the risk of cancer, results are summarized in Table 2 . Restriction fragment length polymorphism was used to analyse germline DNA samples that were extracted from breast cancer patients or controls. Most of these studies comprise of small sample sizes and may be prone to sampling bias.
Cattaneo et al. [42] investigated a sample of the Italian population and found no association between the -160 C/A SNP and breast cancer risk (OR = 1.35, 95 % CI = 0.84-2.17). Lei et al. [37] found the same result among the Swedish as well as Czech populations. But in some studies [39] [40] [41] , positive associations between the -160 C/A polymorphism and breast cancer susceptibility and/or progression were detected. Yu et al. [39] found a significant increase (30% more likely) in risk among CDH1-160A allele carriers. patients across different histologic and molecular subtypes [26] [27] [28] . Invasive lobular breast cancers in most cases do not express E-cadherin [29] [30] [31] , and in a smaller proportion they show only atypical expression. This latter subtype often shows loss of heterozygosity of the wild type allele of CDH1, combined with inactivating mutations of the remaining copy.
The analysis of exon 1 to exon 16 of CDH1 gene mutations have been implicated in breast cancer ( Table 1) . As the genomic transcription is critically dependent on the exact sequence of these elements, the nucleotide changes of these mutations can lead to transcriptional alterations by modifying the affinity of the DNA-binding proteins [32, 33] . These mutations lead to truncated proteins of E-cadherin, abnormal alterations of the E-cadherin's calcium binding sites, or increases in its proteolytic this study, we found significant association between the CDH1 -160 C/A polymorphism and breast cancer in recent studies. -160C/A SNP within the CDH1 promoter region is a functional polymorphism that may affect transcription efficiency in vitro [42] . There is no doubt that E-cadherin inactivation plays an important role in the development of breast cancers. A large number of investigations indicate complete and irreversible inactivation of E-cadherin in lobular breast cancer. These findings implicit E-cadherin's role as a genuine tumor suppressor role in this subclass of breast cancer.
Adjuvant chemotherapy decreases the risk of breast cancer recurrence in patients with breast cancer. In addition, it increases the rate of survival [46] [47] [48] . Despite the limitations of most published studies, the preliminary research described in the literature indicates that E-cadherin polymorphism assessment may be used to evaluate breast cancer susceptibility and aggressiveness. Methods for selection of the patients who are suitable for anti-E-cadherin therapy should be developed and established. Further clinical trials involving the study of E-cadherin polymorphisms should be completed that comprise a large number of patients of different ethnicities. In summary, E-cadherin and its associated signaling pathways play important roles in maintaining functions of breast cancer. In contrast, dysregulation of these factors contributes to breast cancer initiation and progression. Detection of the expression and aberrant alterations of E-cadherin are promising for clinical applications for diagnosis, prognosis and therapy for breast cancer. However, care should be taken due to the tumor promoting Tipirisetti et al. [40] depicted that CDH1 -160A/A genotype is responsible for the occurrence of breast cancer among Indian women. In the recent study, Shabnaz et al [41] found a significant association of CDH1 -160 C/A polymorphism and breast cancer risk in Bangladeshi women for the first time. Taken together, these apparently conflicting data may reflect the important biological function of CDH1 polymorphisms. Due to the small sample sizes of most of the studies, limited numbers of CDH1 polymorphisms examined, and differing ethnicity of the study groups, all of the above findings are considered to be preliminary.
Discussion
This short review focuses on the evidence for a role for E-cadherin in breast cancer predisposition and prognosis. It has an emphasis on studies of the role of the CDH1 gene polymorphisms in breast cancer. Seven studies are included. Additional studies are still needed to evaluate the association between CDH1 gene polymorphisms and breast cancer susceptibility.
Many studies have suggested that SNPs in the E-cadherin (CDH1) gene promoter region contribute to interindividual variation in the production of E-cadherin. Difference in individual E-cadherin level lead to variations in individual susceptibility to cancer [32] . Germline mutations in CDH1 are highly penetrant, with a risk of up to 70% of symptomatic diffuse gastric cancer by the age of 75 years [44] . CDH1 constitutive mutations also account for some familial clustering of lobular breast cancers [45] . In [37] 2002 Stockholm 576/348 N.S. Sarrió et al. [36] 2003 Spain 45/20 N.S. Cattaneo et al. [42] 2006 Central Italy (Lazio) 99/246 N.S. Yu et al. [39] 2006 Taiwan 468/470 Minor allele carriers (rs16260 A) were 30% more likely to be breast cancer cases than women with only the major allele (C). Tipirisetti et al. [40] 2013 Indian 202/250
The frequencies of -160A/A genotypes (p = 0.038) and -160A alleles (p = 0.046) were significantly higher in patients compared to controls. Shabnaz et al. [41] 2015 Bangladesh 310/250 A significant association was found between -160 C/A (rs16260) polymorphisms and breast cancer risk. In case of CDH1 rs16260 polymorphism, C/A heterozygote and combined C/A + A/A genotypes were found to be strongly associated (P = 0.005, OR = 1.67; P = 0.0037, OR = 1.68) with increased risk of breast cancer. The variant A allele also increased the breast cancer risk (P = 0.0058, OR = 1.52).
N.S.: not significant
role of E-cadherin in specific cell context in order not to render development of other tumors during reactivation of E-cadherin for therapy of breast cancer. Further studies of the functions of E-cadherin and the mechanisms of its tumor suppressing and tumor promoting roles are still in need before it can be used for wide application in clinic.
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